Antibody titer trends after SARS-CoV-2 vaccination in patients aged 12-25 years with underlying diseases

被引:0
作者
Kasai, Taketo [1 ]
Yamada, Masaki [1 ]
Funaki, Takanori [1 ]
Tao, Chiaki [1 ]
Myojin, Shota [1 ]
Aiba, Hiroyuki [1 ]
Matsui, Toshihiro [1 ]
Ogimi, Chikara [1 ]
Miyake, Kozue [2 ]
Ueno, Saki [2 ]
Miyairi, Isao [1 ,3 ]
Kato, Hitoshi [4 ]
Shoji, Kensuke [1 ]
机构
[1] Natl Ctr Child Hlth & Dev, Dept Med Subspecialties, Div Infect Dis, 2-10-1 Okura,Setagaya Ku, Tokyo 1578535, Japan
[2] Natl Ctr Child Hlth & Dev, Clin Res Ctr, 2-10-1 Okura,Setagaya Ku, Tokyo 1578535, Japan
[3] Hamamatsu Univ, Dept Pediat, Sch Med, 1-20-1 Handayama,Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan
[4] Natl Ctr Child Hlth & Dev, 2-10-1 Okura,Setagaya Ku, Tokyo 1578535, Japan
关键词
SARS-CoV-2; Vaccination; Immunization; Immunocompromised; BNT162B2; COVID-19; VACCINE;
D O I
10.1016/j.jiac.2024.12.008
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Whereas declines in antibody titers after SARS-CoV-2 vaccination have been reported, most reports are predominantly from adults. Long-term trends in SARS-CoV-2 antibody titers after the first BNT162b2 vaccination series in children and young adults with underlying diseases remain less studied. Methods: This prospective single-center observational cohort study enrolled patients aged 12-25 years with underlying diseases who received the first BNT162b2 vaccination series. At least three longitudinal antibody titers were evaluated during the first year following vaccination. Results: Among 429 study subjects, 61 patients with at least three subsequent antibody titer measurements were included. The median (interquartile range [IQR]) time intervals from the vaccination to the first, second, and third antibody measurements were 43 (30-56), 126 (110-155), and 224 (207-256) days, and antibody titers declined with median (IQR) values of 2310 (1440-3515), 2010 (1165-3055), and 1410 (904-2195) U/mL, respectively. In 35 immunocompetent patients, the antibody titers decreased consistently in each measurement. In contrast, the antibody titers in immunocompromised patients remained stable between the first and second measurements, but declined by the third. A two-way ANOVA revealed that time was a more significant factor than immunocompromised status for the declines in antibody titers. Conclusions: In patients aged 12-25 years with underlying diseases, antibody titers in immunocompromised patients after SARS-CoV-2 vaccination were lower than in immunocompetent patients in the early post- vaccination period, but they maintained titers similar to the immunocompetent counterpart during the longterm follow-up.
引用
收藏
页数:5
相关论文
共 12 条
[1]   Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial [J].
Bergman, Peter ;
Blennow, Ola ;
Hansson, Lotta ;
Mielke, Stephan ;
Nowak, Piotr ;
Chen, Puran ;
Soderdahl, Gunnar ;
Osterborg, Anders ;
Smith, C. I. Edvard ;
Wullimann, David ;
Vesterbacka, Jan ;
Lindgren, Gustaf ;
Blixt, Lisa ;
Friman, Gustav ;
Wahren-Borgstrom, Emilie ;
Nordlander, Anna ;
Gomez, Angelica Cuapio ;
Akber, Mira ;
Valentini, Davide ;
Norlin, Anna-Carin ;
Thalme, Anders ;
Bogdanovic, Gordana ;
Muschiol, Sandra ;
Nilsson, Peter ;
Hober, Sophia ;
Lore, Karin ;
Chen, Margaret Sallberg ;
Buggert, Marcus ;
Ljunggren, Hans-Gustaf ;
Ljungman, Per ;
Aleman, Soo .
EBIOMEDICINE, 2021, 74
[2]   BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting [J].
Dagan, Noa ;
Barda, Noam ;
Kepten, Eldad ;
Miron, Oren ;
Perchik, Shay ;
Katz, Mark A. ;
Hernan, Miguel A. ;
Lipsitch, Marc ;
Reis, Ben ;
Balicer, Ran D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (15) :1412-1423
[3]   Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation [J].
Huang, Alice ;
Cicin-Sain, Caroline ;
Pasin, Chloe ;
Epp, Selina ;
Audige, Annette ;
Mueller, Nicolas J. ;
Nilsson, Jakob ;
Bankova, Andriyana ;
Wolfensberger, Nathan ;
Vilinovszki, Oliver ;
Nair, Gayathri ;
Hockl, Philipp ;
Schanz, Urs ;
Kouyos, Roger D. ;
Hasse, Barbara ;
Zinkernagel, Annelies S. ;
Trkola, Alexandra ;
Manz, Markus G. ;
Abela, Irene A. ;
Mueller, Antonia M. S. .
TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (04) :214.e1-214.e11
[4]   Immunogenicity and safety of SARS-CoV-2 mRNA vaccine in patients with nephrotic syndrome receiving immunosuppressive agents [J].
Kamei, Koichi ;
Ogura, Masao ;
Sato, Mai ;
Nishi, Kentaro ;
Shoji, Kensuke ;
Funaki, Takanori ;
Ogimi, Chikara ;
Ito, Shuichi .
PEDIATRIC NEPHROLOGY, 2023, 38 (04) :1099-1106
[5]   Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months [J].
Levin, Einav G. ;
Lustig, Yaniv ;
Cohen, Carmit ;
Fluss, Ronen ;
Indenbaum, Victoria ;
Amit, Sharon ;
Doolman, Ram ;
Asraf, Keren ;
Mendelson, Ella ;
Ziv, Arnona ;
Rubin, Carmit ;
Freedman, Laurence ;
Kreiss, Yitshak ;
Regev-Yochay, Gili .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (24) :E84-E84
[6]   Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients [J].
Obeid, Michel ;
Suffiotti, Madeleine ;
Pellaton, Celine ;
Bouchaab, Hasna ;
Cairoli, Anne ;
Salvade, Vanja ;
Stevenel, Caroline ;
Hottinger, Rosemary ;
Pythoud, Catherine ;
Coutechier, Lucie ;
Molinari, Laura ;
Trono, Didier ;
Ribi, Camillo ;
Gottardo, Raphael ;
Fenwick, Craig ;
Pascual, Manuel ;
Duchosal, Michel A. ;
Peters, Solange ;
Pantaleo, Giuseppe .
JAMA ONCOLOGY, 2022, 8 (05) :E220446
[7]   Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine [J].
Polack, Fernando P. ;
Thomas, Stephen J. ;
Kitchin, Nicholas ;
Absalon, Judith ;
Gurtman, Alejandra ;
Lockhart, Stephen ;
Perez, John L. ;
Perez Marc, Gonzalo ;
Moreira, Edson D. ;
Zerbini, Cristiano ;
Bailey, Ruth ;
Swanson, Kena A. ;
Roychoudhury, Satrajit ;
Koury, Kenneth ;
Li, Ping ;
Kalina, Warren V. ;
Cooper, David ;
Frenck, Robert W., Jr. ;
Hammitt, Laura L. ;
Tureci, Ozlem ;
Nell, Haylene ;
Schaefer, Axel ;
Unal, Serhat ;
Tresnan, Dina B. ;
Mather, Susan ;
Dormitzer, Philip R. ;
Sahin, Ugur ;
Jansen, Kathrin U. ;
Gruber, William C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (27) :2603-2615
[8]   BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans [J].
Sahin, Ugur ;
Muik, Alexander ;
Vogler, Isabel ;
Derhovanessian, Evelyna ;
Kranz, Lena M. ;
Vormehr, Mathias ;
Quandt, Jasmin ;
Bidmon, Nicole ;
Ulges, Alexander ;
Baum, Alina ;
Pascal, Kristen E. ;
Maurus, Daniel ;
Brachtendorf, Sebastian ;
Loerks, Verena ;
Sikorski, Julian ;
Koch, Peter ;
Hilker, Rolf ;
Becker, Dirk ;
Eller, Ann-Kathrin ;
Gruetzner, Jan ;
Tonigold, Manuel ;
Boesler, Carsten ;
Rosenbaum, Corinna ;
Heesen, Ludwig ;
Kuhnle, Marie-Cristine ;
Poran, Asaf ;
Dong, Jesse Z. ;
Luxemburger, Ulrich ;
Kemmer-Brueck, Alexandra ;
Langer, David ;
Bexon, Martin ;
Bolte, Stefanie ;
Palanche, Tania ;
Schultz, Armin ;
Baumann, Sybille ;
Mahiny, Azita J. ;
Boros, Gabor ;
Reinholz, Jonas ;
Szabo, Gabor T. ;
Kariko, Katalin ;
Shi, Pei-Yong ;
Fontes-Garfias, Camila ;
Perez, John L. ;
Cutler, Mark ;
Cooper, David ;
Kyratsous, Christos A. ;
Dormitzer, Philip R. ;
Jansen, Kathrin U. ;
Tuereci, Oezlem .
NATURE, 2021, 595 (7868) :572-+
[9]   Safety of and antibody response to the BNT162b2 COVID-19 vaccine in adolescents and young adults with underlying disease [J].
Shoji, Kensuke ;
Funaki, Takanori ;
Yamada, Masaki ;
Mikami, Masashi ;
Miyake, Kozue ;
Ueno, Saki ;
Tao, Chiaki ;
Myojin, Shota ;
Aiba, Hiroyuki ;
Matsui, Toshihiro ;
Ogimi, Chikara ;
Kato, Hitoshi ;
Miyairi, Isao .
JOURNAL OF INFECTION AND CHEMOTHERAPY, 2023, 29 (01) :61-66
[10]   Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study [J].
Tartof, Sara Y. ;
Slezak, Jeff M. ;
Fischer, Heidi ;
Hong, Vennis ;
Ackerson, Bradley K. ;
Ranasinghe, Omesh N. ;
Frankland, Timothy B. ;
Ogun, Oluwaseye A. ;
Zamparo, Joann M. ;
Gray, Sharon ;
Valluri, Srinivas R. ;
Pan, Kaije ;
Angulo, Frederick J. ;
Jodar, Luis ;
McLaughlin, John M. .
LANCET, 2021, 398 (10309) :1407-1416